Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
What the Research Shows Recent research on semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has revealed concerning trends about body composition changes: A 2023 analysis of STEP trial data found that approximately 39% of weight lost on semaglutide was lean body mass 1 Research on tirzepatide showed similar patterns, with 30-40% of total weight loss coming from lean tissue 2 Comparative studies indicate GLP-1 users may lose more muscle than people losing weight through diet and exercise alone 3 For context: if you lose 50 pounds on a GLP-1 medication, 15-20 pounds might be muscle mass
HRT is typically continued for as long as symptoms persist and benefits outweigh risks
Following the healthcare providers guidance ensures the best results and helps patients to achieve and maintain the resulting weight loss over the long term
Kravetz L, Leeman S, Regev T et al (2025) The effect of glucagon-like peptide-1 agonists on ocular parameters in idiopathic intracranial hypertension patients: a retrospective study
US$ 22.00
US$ 28.00
US$ 23.83
US$ 20.26
Firepits" loading="lazy"/>
